OAT
Organic anion transporter
Organic anion transporters (OATs), a subfamily of the solute carrier 22 (SLC22) transporters, are localized on the physiological barriers of multiple tissues, such as kidney, liver, brain, placenta, retina, and olfactory mucosa. They are the key players for the translocation of various substances into and out of cells, such as signaling molecules, toxins, and a diverse array of important clinical therapeutics, including antivirals, anti-cancer drugs, antibiotics, anti-hypertensives, and anti-inflammatories.
All Product Categories
-
OAT Related Products (55)
Related Products (55)
-
S-4048
0 ImagesCat. No.: HY-16443CAS No.: 173534-37-7S-4048 is a glucose-6-phosphate translocase modulator and hypoglycemic agent. S-4048 is taken up by hepatocytes via OATP-1 and is rapidly eliminated via the hepatobiliary system in rats. S-4048 blocks glucose-6-phosphate translocase, prevents glucose-6-phosphate from entering the endoplasmic reticulum, and thereby interferes with the glucose-6-phosphatase system (i.e., the final step of hepatic gluconeogenesis and glycogenolysis) to regulate hepatic glucose production. S-4048 completely inhibits glucose production from pyruvate in GLUT2-deficient hepatocytes without affecting the release of cytoplasmic glucose. S-4048 effectively reduces blood glucose levels in rats and has been used in studies related to type 2 diabetes.
-
PF-05221304 tromethamine
0 ImagesCat. No.: HY-137846ACAS No.: 2334472-62-5PF-05221304 tromethamine is an orally active, liver-directed and dual ACC1/ACC2 inhibitor with IC50s of 7.5 nM for rat ACC1, 8.2 nM for rat ACC2. PF-05221304 tromethamine is a substrate for organic anion transport polypeptides. PF-05221304 tromethamine directly improves a variety of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) pathogenic factors.
-
Erlotinib-13C6
0 ImagesCat. No.: HY-50896S1CAS No.: 1211107-68-4Synonyms: CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6Erlotinib-13C6 (CP-358774-13C6) is the 13C-labeled Erlotinib (HY-50896). Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
-
Cabotegravir (Standard)
0 ImagesSynonyms: GSK-1265744 (Standard); S/GSK1265744 (Standard)Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS.
-
URAT1-IN-15
0 ImagesCat. No.: HY-180227URAT1-IN-15 (Compound 9) is an orally active, selective URAT1 inhibitor with an IC50 of 69.81 nM. URAT1-IN-15 inhibits CYP2C9 (IC50 = 8.39 μM). URAT1-IN-15 shows uricosuric activity. URAT1-IN-15 can be used in the research of hyperuricemia.
-
Erlotinib-d8
0 ImagesCat. No.: HY-50896S3CAS No.: 1266656-97-6Synonyms: CP-358774-d8; NSC 718781-d8; OSI-774-d8Erlotinib-d8 (CP-358774-d8) is the deuterated-labeled Erlotinib (HY-50896). Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, as well as the deposition of fibronectin, α-SMA, collagen and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, EGFR inhibitor resistance and renal fibrosis.
-
Lesinurad-d4
0 ImagesCat. No.: HY-15258S1CAS No.: 1850305-60-0Synonyms: RDEA594-d4
-
Pradigastat (Standard)
0 ImagesCat. No.: HY-16278RCAS No.: 956136-95-1Synonyms: LCQ-908 (Standard)Pradigastat (Standard) is the analytical standard of Pradigastat. This product is intended for research and analytical applications. Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro.
-
6-Hydroxyindole (Standard)
0 Images6-Hydroxyindole (Standard) is the analytical standard of 6-Hydroxyindole (HY-W002438). This product is intended for research and analytical applications. 6-Hydroxyindole is an orally active, endogenous long-acting OATP1B1 inhibitor. 6-Hydroxyindole does not alter the cell surface expression or subcellular localization of OATP1B1. 6-Hydroxyindole protects cells against Ferroptosis. 6-Hydroxyindole possesses intrinsic radical-trapping antioxidant activity. 6-Hydroxyindole serves as a component of oxidative hair dyes. 6-Hydroxyindole can be used in research related to renal failure and neurodegenerative diseases.
-
Epaminurad (Standard)
0 ImagesCat. No.: HY-111345RCAS No.: 1198153-15-9Synonyms: UR-1102 (Standard); URC-102 (Standard)Epaminurad (Standard) is the analytical standard of Epaminurad (HY-111345). This product is intended for research and analytical applications. Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research.
-
DRAinh-A250
0 ImagesCat. No.: HY-124706CAS No.: 858747-13-4DRAinh-A250 is an orally active inhibitor of mouse and human SLC26A3 (DRA). DRAinh-A250 inhibits SLC26A3-mediated anion transport, blocks colonic fluid absorption, reduces luminal fluid alkalization in the distal colonic loops of mice, and alleviates Loperamide (HY-156131)-induced constipation in wild-type and cystic fibrosis mice. DRAinh-A250 can be used in the research of constipation and cystic fibrosis-related constipation.
-
Erlotinib mesylate
0 ImagesCat. No.: HY-12008ACAS No.: 248594-19-6Synonyms: CP-358774 mesylate; NSC 718781 mesylate; OSI-774 mesylateErlotinib (CP-358774) mesylate is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib mesylate also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib mesylate blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib mesylate inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, as well as the deposition of fibronectin, α-SMA, collagen and renal injury markers. Erlotinib mesylate is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib mesylate can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, EGFR inhibitor resistance and renal fibrosis.
-
Hydrastine (Standard)
0 ImagesSynonyms: (-)-β-Hydrastine (Standard); (1R,9S)-β-Hydrastine (Standard)Hydrastine (Standard) is the analytical standard of Hydrastine (HY-B0927). This product is intended for research and analytical applications. Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC50=20.7 μM, PC12 cells). Hydrastine also inhibits the organic cation transporter OCT1 (IC50=6.6 μM). Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage.
-
Erlotinib-d4
0 ImagesCat. No.: HY-50896S2CAS No.: 1130852-41-3Synonyms: CP-358774-d4; NSC 718781-d4; OSI-774-d4Erlotinib-d4 (CP-358774-d4) is the deuterated-labeled Erlotinib (HY-50896). Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
-
Epaminurad hydrochloride
0 ImagesCat. No.: HY-111345ACAS No.: 1198153-46-6Synonyms: UR-1102 hydrochloride; URC-102 hydrochlorideEpaminurad (UR-1102) hydrochloride is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad hydrochloride quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad hydrochloride is a uricosuric agent. Epaminurad hydrochloride can be used for gout and hyperuricemia research.
